🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Cliff Asness’s KROS Holdings & Trades

First Buy
Q1 2023
Duration Held
8 Quarters
Largest Add
Q1 2026
+226,020 Shares
Current Position
406,563 Shares
$4.49 M Value

Cliff Asness's KROS Position Overview

Cliff Asness (via Aqr Capital Management LLC) currently holds 406,563 shares of Keros Therapeutics, Inc. (KROS) worth $4.49 M, representing 0.00% of the portfolio. First purchased in 2023-Q1, this short-term holding has been held for 8 quarters.

Based on 13F filings, Cliff Asness has maintained this position in KROS for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 226,020 shares. Largest reduction occurred in Q4 2025, reducing 23,808 shares.

Analysis based on 13F filings available since 2013 Q2

Cliff Asness's Keros Therapeutics (KROS) Holding Value Over Time

Track share changes against reported price movement

Quarterly Keros Therapeutics (KROS) Trades by Cliff Asness

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +226,020 Add 125.19% 406,563 $11.04
Q4 2025 -23,808 Reduce 11.65% 180,543 $20.36
Q3 2025 +133,701 Add 189.24% 204,351 $15.82
Q2 2025 +48,514 Add 219.16% 70,650 $13.35
Q1 2025 +22,136 New Buy 22,136 $10.19
Q3 2023 -11,441 Sold Out 0 $0.00
Q2 2023 +3,850 Add 50.72% 11,441 $40.18
Q1 2023 +7,591 New Buy 7,591 $42.70

Cliff Asness's Keros Therapeutics Investment FAQs

Cliff Asness first purchased Keros Therapeutics, Inc. (KROS) in Q1 2023, acquiring 7,591 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Cliff Asness has held Keros Therapeutics, Inc. (KROS) for 8 quarters since Q1 2023.

Cliff Asness's largest addition to Keros Therapeutics, Inc. (KROS) was in Q1 2026, adding 406,563 shares worth $4.49 M.

According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 406,563 shares of Keros Therapeutics, Inc. (KROS), valued at approximately $4.49 M.

As of the Q1 2026 filing, Keros Therapeutics, Inc. (KROS) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.

Cliff Asness's peak holding in Keros Therapeutics, Inc. (KROS) was 406,563 shares, as reported at the end of Q1 2026.